Education
About Us
Working with TipRanks
Follow Us
Sanofi (FR:SAN)
:SAN
SAN Analyst Ratings
Moderate Buy
12 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SAN Stock 12 Month Forecast
Average Price Target
€111.79
▲(35.61%Upside)
| Highest Price Target€126.61 | Average Price Target€111.79 | Lowest Price Target€94.71 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
€92
Buy
11.60%
Upside
Reiterated
06/19/25
UBS
€115
Buy
39.50%
Upside
Reiterated
07/08/25
Berenberg Bank
€118
Buy
43.13%
Upside
Reiterated
07/03/25
Goldman Sachs
€117→€103
Hold
24.94%
Upside
Reiterated
07/03/25
J.P. Morgan
€110
Hold
33.43%
Upside
Reiterated
07/02/25
Barclays
€125→€115
Buy
39.50%
Upside
Reiterated
07/02/25
Bank of America Securities
€123→€115
Buy
39.50%
Upside
Reiterated
07/01/25
Sanofi's Strong Sales and Promising Growth Justify Buy Rating Despite EPS SetbackWe forecast 1) EPS on sales with sales broadly in-line VA cons, but EPS c5% below cons, mostly higher R&D spend (expect to correct prior to print); 2) -2% vs cons with US Eur2.6bn comprising TRx +c9% QoQ, offset by usual small pricing/mix headwinds. Acceleration from COPD launch sees TRx growth at +c28% YoY, vs +29% and acceleration from +c24% for on continued strong launch; with US TRx still growing c16% YoY (continued windfall sales; 3) GM hardest to forecast, with 90bps YoY improvement, partly reflecting 1Q call commentary that 2/3 of GM improvement in 1Q was product mix/efficiencies (remainder was inventory revaluation in 1Q); 4) R&D 140bps worse YoY (related to SOBI in comparator Q); 5) OOI of -Eur944mn.
Deutsche Bank
€100
Hold
21.30%
Upside
Reiterated
06/24/25
Jefferies
€120
Buy
45.56%
Upside
Reiterated
06/05/25
Guggenheim
€108→€110
Buy
33.43%
Upside
Reiterated
06/02/25
Leerink Partners
―
Buy
―
Reiterated
06/02/25
Bernstein
€124
Buy
50.41%
Upside
Reiterated
06/02/25
Kepler Capital
€95
Hold
15.24%
Upside
Reiterated
05/30/25
HSBC
€130→€115
Buy
39.50%
Upside
Reiterated
04/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
€92
Buy
11.60%
Upside
Reiterated
06/19/25
UBS
€115
Buy
39.50%
Upside
Reiterated
07/08/25
Berenberg Bank
€118
Buy
43.13%
Upside
Reiterated
07/03/25
Goldman Sachs
€117→€103
Hold
24.94%
Upside
Reiterated
07/03/25
J.P. Morgan
€110
Hold
33.43%
Upside
Reiterated
07/02/25
Barclays
€125→€115
Buy
39.50%
Upside
Reiterated
07/02/25
Bank of America Securities
€123→€115
Buy
39.50%
Upside
Reiterated
07/01/25
Sanofi's Strong Sales and Promising Growth Justify Buy Rating Despite EPS SetbackWe forecast 1) EPS on sales with sales broadly in-line VA cons, but EPS c5% below cons, mostly higher R&D spend (expect to correct prior to print); 2) -2% vs cons with US Eur2.6bn comprising TRx +c9% QoQ, offset by usual small pricing/mix headwinds. Acceleration from COPD launch sees TRx growth at +c28% YoY, vs +29% and acceleration from +c24% for on continued strong launch; with US TRx still growing c16% YoY (continued windfall sales; 3) GM hardest to forecast, with 90bps YoY improvement, partly reflecting 1Q call commentary that 2/3 of GM improvement in 1Q was product mix/efficiencies (remainder was inventory revaluation in 1Q); 4) R&D 140bps worse YoY (related to SOBI in comparator Q); 5) OOI of -Eur944mn.
Deutsche Bank
€100
Hold
21.30%
Upside
Reiterated
06/24/25
Jefferies
€120
Buy
45.56%
Upside
Reiterated
06/05/25
Guggenheim
€108→€110
Buy
33.43%
Upside
Reiterated
06/02/25
Leerink Partners
―
Buy
―
Reiterated
06/02/25
Bernstein
€124
Buy
50.41%
Upside
Reiterated
06/02/25
Kepler Capital
€95
Hold
15.24%
Upside
Reiterated
05/30/25
HSBC
€130→€115
Buy
39.50%
Upside
Reiterated
04/28/25
Best Analysts Covering Sanofi
1 Month
xxx
Success Rate
8/15 ratings generated profit
Average Return
-0.45%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of -0.45% per trade.
3 Months
xxx
Success Rate
10/15 ratings generated profit
Average Return
+1.21%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.21% per trade.
1 Year
Success Rate
19/30 ratings generated profit
Average Return
+4.62%
reiterated a buy rating last month
Copying David Risinger's trades and holding each position for 1 Year would result in 63.33% of your transactions generating a profit, with an average return of +4.62% per trade.
2 Years
xxx
Success Rate
15/21 ratings generated profit
Average Return
+9.18%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +9.18% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SAN Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
0
0
Buy
21
24
30
33
23
Hold
10
11
15
14
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
35
45
47
33
Each month's total comprises the sum of three months' worth of ratings.
SAN Financial Forecast
SAN Stock Forecast FAQ
What is FR:SAN’s average 12-month price target, according to analysts?
Based on analyst ratings, Sanofi’s 12-month average price target is 111.79.
What is FR:SAN’s upside potential, based on the analysts’ average price target?
Sanofi has 35.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sanofi a Buy, Sell or Hold?
Sanofi has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.
What is Sanofi’s share price target?
The average share price target for Sanofi is 111.79. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €126.61 ,and the lowest forecast is €94.71. The average share price target represents 35.61% Increase from the current price of €82.44.
The highest analyst share price target is €126.61 ,and the lowest forecast is €94.71. The average share price target represents 35.61% Increase from the current price of €82.44.
What do analysts say about Sanofi?
Sanofi’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of Sanofi?
To buy shares of FR:SAN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.